Compare Avantis US Small Cap Value ETF (AVUV) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs DexCom, Inc. — how do they compare? Avantis US Small Cap Value ETF trades at $127.5, while DexCom, Inc. trades at $90.54 (market cap $33.79B). Which is the better fit depends on your goals.
| AVUV | DXCM | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $89.53 |
52-Week Low | $93.93 | $54.84 |
Market Cap | — | $33.79B |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $127.50, up 0.39% with a bullish technical outlook supported by moving averages. The small-cap value ETF is benefiting from strong sector performance, with the Russell 2000 up approximately 20% year-to-date according to 24/7 Wall Street (July 17, 2026). Recent dividend activity includes a $0.44 distribution scheduled for June 2026.
The outlook remains positive as small-cap value continues outperforming growth stocks, with AVUV capturing this premium. Key risks include interest rate sensitivity and regional bank exposure, while institutional sentiment appears favorable given the ETF's role in diversifying tech-heavy portfolios.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
